Dr. Daniel M. Anderson
Claim this profileRegions Hospital
Expert in Skin Cancer
Expert in Cancer
60 reported clinical trials
108 drugs studied
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
metastatic
2Cancer
Global LeaderStage IV
Stage III
NTRK positive
Affiliated Hospitals
Clinical Trials Daniel M. Anderson is currently running
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
More about Daniel M. Anderson
Clinical Trial Related4 years of experience running clinical trials · Led 60 trials as a Principal Investigator · 30 Active Clinical TrialsTreatments Daniel M. Anderson has experience with
- Nivolumab
- Pembrolizumab
- Carboplatin
- Biospecimen Collection
- Paclitaxel
- Cabozantinib S-malate
Breakdown of trials Daniel M. Anderson has run
Skin Cancer
Cancer
Gastroesophageal Junction Adenocarcinoma
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel M. Anderson specialize in?
Daniel M. Anderson focuses on Skin Cancer and Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Daniel M. Anderson currently recruiting for clinical trials?
Yes, Daniel M. Anderson is currently recruiting for 27 clinical trials in Saint Paul Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Daniel M. Anderson has studied deeply?
Yes, Daniel M. Anderson has studied treatments such as Nivolumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Daniel M. Anderson?
Apply for one of the trials that Daniel M. Anderson is conducting.
What is the office address of Daniel M. Anderson?
The office of Daniel M. Anderson is located at: Regions Hospital, Saint Paul, Minnesota 55101 United States. This is the address for their practice at the Regions Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.